Empacoza Plus 25/5 mg 30 tablets

Available at Pharmaegy Pharmacy. Use as directed by your doctor.

Empacoza Plus 5 mg/25 mg 30 Tablets Composition Each film-coated tablet contains: Empacoza Plus 5/25 mg: Empagliflozin 25 mg and Linagliptin 5 mg Description Empacoza Plus is a fixed-dose combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated for adults with type 2 diabetes mellitus. It works by promoting urinary glucose excretion and enhancing incretin activity to improve blood glucose control. Empacoza Plus is intended for patients whose blood sugar levels are not adequately controlled with metformin and/or sulphonylurea and one of the individual components. Indications for Use Adults (≥18 years) with type 2 diabetes mellitus: Inadequate glycemic control on metformin and/or sulphonylurea and one of the components of Empacoza Plus Patients already treated with the free combination of empagliflozin and linagliptin Dosage and Method of Administration Starting dose: One tablet of 10 mg empagliflozin / 5 mg linagliptin once daily If needed for better glycemic control: Increase to one tablet of 25 mg empagliflozin / 5 mg linagliptin once daily Renal impairment: Do not initiate if eGFR or CrCl <60 mL/min; reduce dose or discontinue if eGFR or CrCl persistently <45 mL/min Hepatic impairment: Not recommended in severe cases Elderly: Use caution in patients ≥75 years old; not recommended for ≥85 years old Contraindications Hypersensitivity to empagliflozin, linagliptin, or any excipients Type 1 diabetes mellitus Diabetic ketoacidosis End-stage renal disease or patients on dialysis Precautions Risk of diabetic ketoacidosis with atypical presentation Monitor renal function regularly Increased risk of hypoglycemia with insulin or sulphonylurea Risk of acute pancreatitis, particularly in patients with history of pancreatitis Monitor volume status in case of dehydration risk Risk of urinary/genital infections Possible hepatic injury or elevated hematocrit Not recommended in patients aged ≥85 years Pregnancy and Breastfeeding Not recommended during pregnancy and breastfeeding due to lack of data Side Effects Very common: Urinary tract infections (7.5–8.5%) Serious: Diabetic ketoacidosis (<0.1%), pancreatitis (0.2%), hypersensitivity (0.6%), hypoglycemia (2.4%) Others: Genital infections, volume depletion, rash, hepatic enzyme elevations Storage Conditions Store below 30°C. Keep out of reach of children. Packaging Carton box contains 3 blisters of 10 film-coated tablets and a package insert.